FAQ

Chronic myeloproliferative disorder

Known as: Myeloproliferative Disorder, MPD, Myeloproliferative Neoplasm 
A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1953-2018
020040019532017

Related topics

Related topics

14 relations
Bone MarrowBone marrow stem cellEPSTI1 geneEPSTI1 wt Allele
(More)

Broader (1)

Myeloproliferative disease

Related mentions per year

Related mentions per year

1936-2019
19401960198020002020
Chronic myeloproliferative disorder
cancer cell
Bone Marrow
Neoplastic Cell
Myeloproliferative disease
Hemopoietic tissue

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
The oncogenetic events that transform chronic myeloproliferative neoplasms (MPN) to acute myeloid leukemias (AML) are not well… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms.
Chromosomal abnormalities are frequent in myeloid malignancies, but in most cases of myelodysplasia (MDS) and myeloproliferative… (More)
  • table 1
  • figure 1
  • figure 2
  • table 3
  • figure 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.
Reporting of myelodysplastic syndromes (MDSs) and chronic myeloproliferative disorders (CMDs) to population-based cancer… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2007
Highly Cited
2007
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations
JAK2V617F and MPLW515L/K represent recently identified mutations in myeloproliferative disorders (MPD) that cause dysregulated… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders.
BACKGROUND Thrombosis of splanchnic or cerebral veins is a typical manifestation of polycythemia vera (PV) or essential… (More)
  • table 1
  • table 2
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis.
The diagnosis of an underlying chronic myeloproliferative disorder (CMPD) is often problematic in patients with primary… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.
The analysis of rare chromosomal translocations in myeloproliferative disorders has highlighted the importance of aberrant… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.
A somatic mutation in the JH2 autoinhibitory domain of the Janus kinase 2 (JAK2) tyrosine kinase was recently described in… (More)
  • figure 1
  • table 1
Is this relevant?
Highly Cited
2004
Highly Cited
2004
JunB Deficiency Leads to a Myeloproliferative Disorder Arising from Hematopoietic Stem Cells
The AP-1 transcription factor JunB is a transcriptional regulator of myelopoiesis. Inactivation of JunB in postnatal mice results… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
Highly Cited
1987
Highly Cited
1987
RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes.
We report on investigations aimed at detecting mutated RAS genes in a variety of preleukemic disorders and leukemias of myeloid… (More)
Is this relevant?